Copyright
©The Author(s) 2023.
World J Clin Cases. May 16, 2023; 11(14): 3267-3274
Published online May 16, 2023. doi: 10.12998/wjcc.v11.i14.3267
Published online May 16, 2023. doi: 10.12998/wjcc.v11.i14.3267
Investigation | On admission | 2 wk later | 3 mo later | Reference range |
T3 (nmol/L) | 1.57 | 1.14 | 2.25 | 0.89 to 2.45 |
T4 (nmol/L) | 191.37 | 128.27 | 132.69 | 62.68 to 150.84 |
TSH (µIU/mL) | < 0.01 | 0.01 | 3.84 | 0.35 to 4.94 |
FT3 (pmol/L)) | 5.27 | 3.87 | 4.71 | 2.63 to 5.71 |
FT4 (pmol/L) | 24.1 | 16.27 | 10.91 | 9.1 to 19.24 |
TPO-Ab (IU/mL) | > 1000.00 | > 1000.00 | 363 | 0 to 5.61 |
TG-Ab (IU/mL) | 226.08 | 140.84 | 218 | 0 to 4.11 |
- Citation: Gao MJ, Xu Y, Wang WB. Immune checkpoint inhibitor therapy-induced autoimmune polyendocrine syndrome type II and Crohn’s disease: A case report. World J Clin Cases 2023; 11(14): 3267-3274
- URL: https://www.wjgnet.com/2307-8960/full/v11/i14/3267.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i14.3267